(E)-5-(4-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]phenyl)-2-(pyridin-3-yl)oxazole | 89764-17-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-5-(4-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]phenyl)-2-(pyridin-3-yl)oxazole
• 英文别名: 5-[4-[(2E)-3,7-dimethylocta-2,6-dienoxy]phenyl]-2-pyridin-3-yl-1,3-oxazole
• CAS: 89764-17-0
• 化学式: C₂₄H₂₆N₂O₂
• 分子量: 374.483
• InChiKey: SCOSSTFYVOJNFI-CPNJWEJPSA-N

物化性质

• 沸点：
  557.6±60.0 °C(Predicted)
• 密度：
  1.074±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  48.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(5-噁唑基)苯酚 在 copper(l) iodide 、 sodium hydride 、 sodium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 生成 (E)-5-(4-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]phenyl)-2-(pyridin-3-yl)oxazole
  参考文献：
  名称：

  Structure–Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells

  摘要：

  Targeted therapies for ER+/PR+ and HER2-amplified breast cancers have improved patient survival, but there are no therapies for triple negative breast cancers (TNBC) that lack expression of estrogen and progesterone receptors (ER/PR), or amplification or overexpression of HER2. Gene expression profiling of TNBC has identified molecular subtypes and representative cell lines. An extract of the Texas native plant Amyris texana was found to have selective activity against MDA-MB-453 cells, a model of the luminal androgen receptor (LAR) subtype of TNBC. Bioassay-guided fractionation identified two oxazole natural products with selective activity against this cell line. Conducted analog synthesis and structure activity relationship studies provided analogs with more potent and selective activity against two LAR. subtype cell line models, culminating in the discovery of compound 30 (CIDD-0067106). Lead compounds discovered have potent and selective antiproliferative activities, and mechanisms of action studies show they inhibit the activity of the mTORC1 pathway.

  DOI：

  10.1021/acs.jmedchem.7b01228